t(1;2)(q21;p23) and t(2;3)(p23;q21): two novel variant translocations of the t(2;5)(p23;q35) in anaplastic large cell lymphoma.

Cytogenetic investigations in two cases of anaplastic large cell lymphoma (ALCL) showed novel variants of the classical (2;5)(p23;q35) translocation, namely a t(1;2)(q21;p23) and a t(2;3)(p23;q21). The tumor cells in both cases gave positive immunohistochemical labeling for ALK protein (with both monoclonal and polyclonal antibodies), demonstrating that these translocations induce aberrant expression of this kinase and suggesting that genes other than NPM can activate the ALK gene in ALCL. These two cases were shown by an in vitro kinase assay to express ALK kinases (104 kD and 97 kD, respectively), which differed in size from the classical NPM-ALK fusion product (80 kD). Moreover, ALK expression was confined to the cytoplasm of the tumor cells in each case, supporting the hypothesis that the observed nuclear localization of NPM-ALK in classical ALCL is not the site of oncogenic activity of the ALK kinase.

[1]  A. Rosenwald,et al.  Biochemical detection of novel anaplastic lymphoma kinase proteins in tissue sections of anaplastic large cell lymphoma. , 1999, The American journal of pathology.

[2]  S. Pileri,et al.  ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. , 1998, The American journal of pathology.

[3]  A. Rosenwald,et al.  Chromosomal abnormalities in nodal and extranodal CD30+ anaplastic large cell lymphomas: Infrequent detection of the t(2;5) in extranodal lymphomas , 1998, Genes, chromosomes & cancer.

[4]  S. Pileri,et al.  ALK-positive lymphoma: a single disease with a broad spectrum of morphology. , 1998, Blood.

[5]  K. Pulford,et al.  Nucleolar localization of the nucleophosmin-anaplastic lymphoma kinase is not required for malignant transformation. , 1998, Cancer research.

[6]  E. Campo,et al.  The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements. , 1997, The American journal of pathology.

[7]  K. Pulford,et al.  Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis , 1997, Molecular and cellular biology.

[8]  K. Pulford,et al.  Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. , 1997, Blood.

[9]  D. Weisenburger,et al.  Detection of the t(2;5)(p23;q35) and NPM-ALK fusion in non-Hodgkin's lymphoma by two-color fluorescence in situ hybridization. , 1997, Blood.

[10]  A. Rosenwald,et al.  Translocation t(2;5) is not a primary event in Hodgkin's disease. Simultaneous immunophenotyping and interphase cytogenetics. , 1996, The American journal of pathology.

[11]  H. Satoh,et al.  Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[12]  A. Bernheim,et al.  High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. , 1996, Blood.

[13]  M. Schrappe,et al.  Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.

[15]  H. Satoh,et al.  Diagnosis of t(2;5)(p23;q35)-associated Ki-1 lymphoma with immunohistochemistry. , 1994, Blood.

[16]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.

[17]  G. Rodrigues,et al.  Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase , 1993, Molecular and cellular biology.

[18]  G. Basso,et al.  A NOVEL VARIANT TRANSLOCATION t(2;13) (p23;q34) IN Ki‐1 LARGE CELL ANAPLASTIC LYMPHOMA , 1990, British journal of haematology.

[19]  R. Warnke,et al.  CD30‐positive large cell lymphomas (‘Ki‐1 lymphoma’) are associated with a chromosomal translocation involving 5q35 , 1990, British journal of haematology.

[20]  R. Larson,et al.  The t(2;5)(p23;q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma. , 1989, Leukemia.

[21]  K. Lennert,et al.  The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. , 1985, Blood.

[22]  Iscn International System for Human Cytogenetic Nomenclature , 1978 .